Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, Asia Pacific, the Middle East, Africa, and Latin America. The company is headquartered in Pleasanton, California.
| Revenue (TTM) | $3.46B |
| Gross Profit (TTM) | $2.59B |
| EBITDA | $1.08B |
| Operating Margin | 29.60% |
| Return on Equity | 14.40% |
| Return on Assets | 7.58% |
| Revenue/Share (TTM) | $21.15 |
| Book Value | $44.83 |
| Price-to-Book | 5.90 |
| Price-to-Sales (TTM) | 13.14 |
| EV/Revenue | 10.63 |
| EV/EBITDA | 34.17 |
| Quarterly Earnings Growth (YoY) | 39.50% |
| Quarterly Revenue Growth (YoY) | 17.60% |
| Shares Outstanding | $161.91M |
| Float | $148.28M |
| % Insiders | 8.62% |
| % Institutions | 93.36% |
Volatility is currently contracting
VEEV's AI-powered Study Builder Agent automates clinical study setup, cutting manual work while strengthening its connected Clinical Data ecosystem.
Veeva (VEEV) reported earnings 30 days ago. What's next for the stock?
Standards-first agent delivers faster and more consistent EDC and DQS builds PLEASANTON, Calif., Sept. 24, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Veeva Study Builder Agent, a new AI solution that configures Veeva EDC and Veeva DQS (Data Quality System) directly from a study protocol.
VEEV launches Falcon Router to automate biopharma case routing, deepening AI integration across regulated life sciences workflows.
With 190 live customers and 14 top 20 biopharma commitments, Vault CRM is the fastest path to AI PLEASANTON, Calif., Sept. 23, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced a new top 20 biopharma commitment, adding to recent selections by Amgen, Biogen, Eli Lilly and Company, and Regeneron.
VEEV expands its decade-long Amgen partnership with a global Vault CRM rollout, reinforcing enterprise adoption and commercial subscription growth.
PLEASANTON, Calif., Sept. 21, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Veeva Falcon Router, an industry-specific agent to identify and route potential safety adverse event reports, product quality complaints, and medical inquiries to the correct teams with speed and consistency.
Veeva (VEEV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Veeva Systems (VEEV) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, VEEV broke through the 20-day moving average, which suggests a short-term bullish trend.
Agentic CRM foundation to help accelerate the delivery of innovative medicines to patients worldwide PLEASANTON, Calif., Sept. 15, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Amgen plans to deploy Veeva Vault CRM globally, building on a collaboration spanning more than a decade.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on VEEV and any ticker you trade — then tracks every position and per-strategy win rate.
